Indiana AG Joins Lawsuit Challenging DEA Cannabis Rescheduling

Indiana Joins Multi-State Legal Challenge

Indiana's attorney general has formally joined a multi-state lawsuit seeking to halt the DEA's rescheduling of cannabis to Schedule III. The legal filing, submitted to federal court this week, argues that the rescheduling process violates administrative procedure requirements and exceeds the DEA's statutory authority under the Controlled Substances Act.

The lawsuit names the DEA and the Department of Justice as defendants. Indiana joins at least a dozen other states in the litigation. Most haven't authorized medical cannabis programs.

Core Legal Arguments

The complaint challenges the DEA's reliance on HHS scientific review and argues the agency failed to conduct independent analysis. Plaintiffs assert that the Administrative Procedure Act requires the DEA to demonstrate substantial evidence supporting rescheduling, not defer to another agency's recommendation.

Plaintiffs also contend that cannabis meets the statutory criteria for Schedule I classification due to lack of accepted medical use in treatment in the United States. That position contradicts 38 state medical programs.

Timeline and Procedural Status

The DEA published its Notice of Proposed Rulemaking on cannabis rescheduling in December 2024, triggering a 60-day public comment period that closed in February 2025. The agency hasn't yet issued a final rule. This lawsuit seeks preliminary injunction to prevent the rule from taking effect.

Federal courts typically defer to agency expertise in rescheduling cases. Plaintiffs argue procedural defects justify judicial intervention.

Impact on Medical Cannabis Patients

If the lawsuit succeeds in blocking rescheduling, medical cannabis businesses would remain subject to 280E tax penalties that prohibit standard business deductions. Industry analysts estimate 280E costs operators 40-70% effective tax rates. Those rates force price increases that reduce patient access.

The litigation creates uncertainty for operators planning capital investments based on anticipated Schedule III tax relief.

Rescheduling wouldn't change state-level legality, but it would remove federal tax barriers and potentially ease banking restrictions.

Indiana's Cannabis Policy Landscape

Indiana hasn't authorized medical or adult-use cannabis programs and maintains criminal penalties for possession. The state's participation in the lawsuit aligns with its opposition to federal policy changes that could normalize cannabis commerce.

Neighboring states Michigan, Illinois, and Ohio have operational medical and adult-use markets. That creates cross-border enforcement challenges for Indiana law enforcement.

Broader Coalition Strategy

The multi-state coalition includes attorneys general from states with restrictive cannabis laws and overlaps with groups that opposed federal banking reform. Legal experts note the lawsuit faces high procedural hurdles, as courts rarely overturn agency rescheduling decisions absent clear statutory violations.

Similar litigation challenging the DEA's 2016 denial of rescheduling petitions was dismissed. Courts cited standing and ripeness grounds.

What Happens Next

The court will rule on the preliminary injunction motion within 30-60 days, determining whether the DEA can finalize the rescheduling rule while litigation proceeds. A ruling in favor of plaintiffs would freeze the rescheduling process indefinitely.

For complete legal background and related challenges, see the CannIntel topic hub on DEA rescheduling legal challenges. The next procedural milestone is the government's response brief, due within 21 days of service.